Wanbangde Pharmaceutical Holding Group Co Ltd

WP107, a new drug for myasthenia gravis independently developed by Wanbangde Pharmaceutical, a wholly owned subsidiary of ST Wanbang, has received review approval from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University for its multiple-dose escalation clinical trial. WP107 is an oral solution of huperzine A that is more patient-friendly for those with difficulty swallowing. It has previously obtained orphan drug designation from the U.S. FDA and clinical trial approvals in both China and the United States, and received FDA approval for the multiple-dose escalation clinical trial in July 2026. This approval will allow the evaluation of pharmacokinetics, safety, and tolerability of multiple doses in healthy participants. The company cautioned that drug development is characterized by high investment, high risk, and long cycles, and will not affect performance in the short term.

ST Wanbang's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., recently received the Drug Registration Certificate for Sulpiride Tablets issued by the National Medical Products Administration. The specification is 0.1 grams, and the registration classification is chemical drug category 3, which is deemed to have passed the generic drug quality and efficacy consistency evaluation. Sulpiride Tablets are included in the 2025 National Medical Insurance Drug List and the 2026 National Essential Drug List. As a benzamide antipsychotic, it is used to treat schizophrenia, has some efficacy for depressive symptoms, and also has antiemetic and gastric secretion inhibitory effects. The company stated that this approval enriches its product line for antipsychotic medications and strengthens the advantage of its integrated model of active pharmaceutical ingredients and finished drugs. At the same time, it cautioned that drug production and sales are affected by factors such as national policies and market conditions, and there is considerable uncertainty.

As of the close on July 23, 99 A-share biomedical companies have released their 2026 half-year earnings forecasts, with 60 projecting growth in net profit attributable to the parent and 39 forecasting a decline. Fushine Pharma expects net profit attributable to the parent to rise by 2,487 percent to 3,204 percent, Joinn Laboratories anticipates an increase of 884.9 percent to 1,377.4 percent, and Medicilon, Haisco Pharmaceutical, and ST Wanbang also see maximum growth exceeding 500 percent. The chemical pharmaceutical sector is broadly positive, with 25 of the 36 companies that issued forecasts expecting growth. The biologics segment is underperforming, with only 2 of the 9 companies that issued forecasts projecting an increase. Out-licensing of innovative drugs overseas is active, with total out-licensing deal value in the first half reaching approximately 110 billion US dollars. Haisco Pharmaceutical achieved significant performance growth through multiple out-licensing deals. The price of laboratory monkeys continues to rise, with the unit price of cynomolgus monkeys climbing to 178,000 yuan, driving substantial profit forecast increases for CRO companies such as Joinn Laboratories and Medicilon.

ST Wanbang announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Group has independently developed a new drug WP107, an oral solution of huperzine A, for the treatment of generalized myasthenia gravis. It has recently received approval from the US Food and Drug Administration to conduct a multi-dose escalation clinical trial in healthy study participants.